Overview

Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease

Status:
Recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

EXAMINE-CAD-DZHK22 is a prospective, randomized, double-blind, placebo-controlled, crossover trial investigating the efficacy of beta blocker (bisoprolol) and calcium channel blocker (diltiazem) therapy in symptomatic patients with non-obstructed coronary arteries according to coronary physiological testing results.

Phase:

Phase 4

Details

Lead Sponsor:

Charite University, Berlin, Germany

Collaborator:

Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

Treatments:

Bisoprolol
Diltiazem